We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Long-Read Sequencing to Improve Diagnosis Rate of Rare Diseases

By LabMedica International staff writers
Posted on 28 Jan 2025
Image: Researcher Shloka Negi analyzes long-read sequencing data in the UC Santa Cruz Computational Genomics lab (Photo courtesy of UC Santa Cruz)
Image: Researcher Shloka Negi analyzes long-read sequencing data in the UC Santa Cruz Computational Genomics lab (Photo courtesy of UC Santa Cruz)

Rare genetic diseases affect one in every 10 people globally, yet around 50% of cases remain undiagnosed despite advances in genetic technology and testing. The diagnosis process can take several years, especially for children, due to the limitations of current clinical testing methods, such as short-read sequencing, which often misses crucial genomic information. Researchers are now focusing on long-read sequencing as a promising alternative to speed up diagnoses and provide a more comprehensive dataset, potentially eliminating the need for multiple specialized tests.

A study led by researchers at the University of California - Santa Cruz (Santa Cruz, CA, USA) explored the potential of long-read sequencing for diagnosing rare monogenic diseases, which are caused by disruptions in a single gene. The study, published in The American Journal of Human Genetics, found that long-read sequencing could drastically reduce the time for diagnosis from years to days and at a significantly lower cost. The study utilized nanopore sequencing, a technique developed at UCSC, which provided end-to-end reads of the patients’ genomes at approximately USD 1,000 per sample, with data analysis costing around USD 100.

The research involved analyzing 42 patients with rare diseases, some of whom had been diagnosed through traditional short-read methods, while others remained undiagnosed. The long-read sequencing approach provided a more exhaustive dataset, identifying additional rare candidate variants, long-range phasing, and methylation information that short-read sequencing could not capture. This method enabled the researchers to provide conclusive diagnoses for 11 of the 42 patients, including cases of congenital adrenal hypoplasia, disorders of sex development, and neurodevelopmental disorders. On average, long-read sequencing covered 280 genes with significant protein-coding regions that had been missed by short reads, making the diagnosis process faster, more comprehensive, and more cost-effective.

One of the primary advantages of long-read sequencing is its ability to read long stretches of DNA at once, which helps overcome the limitations of short-read sequencing, particularly in complex genomic regions. Furthermore, it provides phasing data, which helps clinicians understand which variants were inherited from each parent, offering valuable insights for genetic diagnoses. The study suggests that long-read sequencing has the potential to transform the diagnosis of rare genetic diseases, offering a more efficient and effective approach to patient care and treatment.

“Long read sequencing is likely the next best test for unsolved cases with either compelling variants in a single gene or a clear phenotype,” said Shloka Negi, a UC Santa Cruz BME Ph.D. student who is the paper’s first author. “It can serve as a single diagnostic test, reducing the need for multiple clinical visits and transforming a years-long diagnostic journey into a matter of hours.”

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Drug Testing Assays
Atellica DT 250 Analyzer
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]

Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more